著者

永廣 和美 荻野 千尋 大本 暢子 杉原 蕗子 松林 照久 西庄 京子 栄田 敏之 奥村 勝彦

出版者

一般社団法人 日本医療薬学会

雑誌

日本医療薬学会年会講演要旨集

巻号頁・発行日

vol.11, 2001

著者

栄田 敏之 中村 任 奥村 勝彦 栃尾 信治 長田 俊治

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.28, no.6, pp.594-598, 2002-12-10 (Released:2011-03-04)

参考文献数

7

被引用文献数

3 3

---

Dissolution tests of acetaminophen filled into the gelatin capsules (SHIONOGI QUALICAPS, Japan) and hydroxypropylmethylcellulose (HPMC) capsules (SHIONOGI QUALICAPS, Japan) were performed after the cap-sules were stored under conditions of 30°C/60%RH for one year, 40°C/75%RH for 6 months, or 60°C for one week. The Japanese Pharmacopoeia 1st fluid, acetic acid buffer (pH4.0), Japanese Pharmacopoeia 2nd fluid and purified water were used as dissolution media. The dissolution profiles of the gelatin capsules changed significantly in comparison to those of the initial profiles after the capsules were stored at 40°C/75%RH for 6 months or 60°C for one week. On the other hand, no delay in dissolution was observed for the HPMC capsules.Dissolution tests were additionally conduced using three commercially available HPMC capsules (SHIONOGI QUALICAPS, Japan ; CAPSUGEL, USA ; SHOGHUN, Korea), and the dissolution profiles of the HPMC capsules of SHIONOGI QUALICAPS were thus found to be independent of the dissolution medium, while the others showed different dissolution profiles depending on the dissolution medium.

著者

船越 順子 濱名 則子 岩城 晃一 松林 照久 西庄 京子 栄田 敏之 奥村 勝彦

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.27, no.6, pp.548-552, 2001-12-10 (Released:2011-03-04)

参考文献数

4

被引用文献数

1 1

---

Follow-up case by telephone was conducted for the discharged patients, who had received the medication consulting services from clinical pharmacists of Kobe university hospital. In this trial, we focused on the patients in the Department of Circulation and Respiratory Diseases. The follow-up case by telephone was carried out from the time of discharge until the next visit (almost 2 weeks after discharge). The patients consisted of 30 men and 17 women (average age was 66.9 years old). By telephone, the following issues were questioned; 1 : medication compliance, 2 : side effects and/or the changes of physical condition, 3 : other issues (such a when an inappropriate use of medicine had been suspected during hospitalization). When the patients so desire they could come in for a check-up anytime. More than about 90% of patients reported to keep good medication compliance and to have no significant side effects. However, 34% of patients claimed a slight of change in their physical condition including dropsical swelling, boiling and gasping. The claims were found more frequency in patients who had been suspected of inappropriately taking their medication. Follow-up care by telephone was found to be an effective way to avoid any kind of risks including the discontinuation of medicine. As a result, although further examinations should be addressed, follow-up care by telephone appears to be a good way to ensure the appropriate use of medicine.

著者

高橋 悠子 中村 任 守屋 友加 白木 孝 林 伸英 熊谷 俊一 岡村 昇 八木 麻理子 竹島 泰弘 松尾 雅文 栄田 敏之 奥村 勝彦

出版者

日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.32, no.11, pp.1111-1116, 2006-11-10

参考文献数

23

---

Recently, high dose gentamicin (GM) has started to be used for the treatment of Duchenne muscular dystrophy (DMD). Previously, since the intravenous infusion of GM for 1h once a week at a dose of 7.5mg/kg/day had caused no significant adverse events in a course of therapy lasting 6 months, we decided to try conducting such therapy for four courses in the present study. We continuously assessed renal function by monitoring serum creatinine, serum cystatin C (Cys-C), serum urea nitrogen (BUN), urinary β_2-microglobulin and urinary N-acetyl-β-D-glucosaminidase (NAG) activity. Serum creatinine levels were found to be much lower than the normal range, while, at 0.65 to 0.78μg/mL, serum Cys-C levels, were within the normal range and so was BUN, suggesting that the glomerular filtration rate in the DMD patients receiving GM therapy was being maintained in the normal range. Therapeutic drug monitoring of GM indicated that it was being rapidly eliminated from the systemic circulation though a slight elevation of urinary NAG activity in 1 patient indicated the possibility of impaired renal proximal tubules. It will thus be necessary to optimize our patient management strategy.